Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Advanced Human Imaging ( (AU:AHI) ) has issued an update.
Advanced Health Intelligence Ltd has been granted a 31-day extension by AusIndustry to finalize its FY2024 R&D reimbursement submission, allowing the company to include international R&D expenditures in its claim. This extension is crucial for AHI as it anticipates receiving approximately AUD $1.1 million, which will support its operational execution during a critical phase of commercial expansion. The company’s consistent R&D reimbursements since 2017 highlight its commitment to innovation in the med-tech sector, while its expanding patent portfolio and global R&D activities reinforce its position as a leader in digital health. Additionally, AHI is pursuing an R&D Advance Facility for AUD $750,000, which, combined with the expected reimbursement, will strengthen its cash flow position with up to AUD $1,850,000 in non-dilutive capital.
More about Advanced Human Imaging
Advanced Health Intelligence Ltd (AHI) operates in the health technology industry, offering innovative smartphone-based health risk identification solutions. These solutions enable individuals to conduct comprehensive health assessments using smartphone sensor technology, which can identify risk markers for various health conditions. The data collected can be shared with healthcare providers, insurers, and other stakeholders to facilitate timely medical interventions. AHI is known for its pioneering work in digital health care, particularly in developing advanced data capture techniques and predictive modelling for health risk assessment.
Technical Sentiment Signal: Sell
Current Market Cap: A$20.52M
For a thorough assessment of AHI stock, go to TipRanks’ Stock Analysis page.